Feb. 4 at 10:50 PM
$VNDA
In the past, I had called VNDA the single best still relatively undiscovered underapreciated biotech firm (it is now my 2nd best, behind SLS) …. However, VNDA still looks great: Market Cap of
$490 mill YET HAS
$294 mill in cash, no LTD, and expected sales of current products of over
$250 mill and DEEP PIPELINE …. And yes, Bysanti, coming up on FEB 21st, is BIG for them with estimates of
$1.2 BILLION REV for them with it per year …. BUT THE HOME RUN is going to be Tradipiant for GL-1 nausea …. That is why Big Pharma will front run it and do a buyout sometime over the next 3-6 months ….. The HUGE HUGE HUGE market for tradipitant will be the
$15 BILLION GL-1 nausea market today, WHICH IS growing to
$45-
$60 BILLION BY 2030!!! That is why a GL-1 Pharma will do a buyout soon !! ….. VNDA now becomes an instant takeover target at about min of
$22 to
$26 by a GL-1 Big Pharma within the next 3-6 months !!!
